|Mr. Zhen Tao Wu||Exec. Chairman||636k||N/A||1954|
|Mr. Jin-Yi Lee||CEO & Director||549k||N/A||1958|
|Mr. Ka Chi Siu||Fin. Director & Director||282k||N/A||1963|
|Mr. Patrick Sung||Controller & Director||251k||N/A||1962|
|Mr. Chi-Hung Yiu||Company Sec.||N/A||N/A||1993|
Cathay International Holdings Limited, an investment holding company, invests and operates in the healthcare sector in the People's Republic of China. It operates through five segments: Lansen, Haizi, Natural Dailyhealth, Botai, and Hotel Operations. The Lansen segment manufactures, markets, and sells pharmaceuticals, cosmeceutical products, plant extracts, and healthcare products. This segment focuses on the rheumatic specialty prescription western pharmaceuticals for the treatment of autoimmune rheumatic diseases and dermatology indications; develops, manufactures, and distributes rheumatic drugs; and sells diagnostic kits and cosmeceutical products. The Haizi segment manufactures, markets, and sells inositol and its by-product, di-calcium phosphate. The Natural Dailyhealth segment provides non-inositol plant extracts, such as bilberry, ginkgo extract, and ginseng extract for use as ingredients in health products. The Botai segment produces and sells collagen injectable fillers; and develops collagen related products. The Hotel Operations segment owns and operates The Crowne Plaza Hotel and Suites Landmark Shenzhen, a five-star hotel located in the Lowu district of Shenzhen in the People's Republic of China. This segment's hotel consists of 312 rooms and suites, and banquet and meeting facilities. Cathay International Holdings Limited is based in Central, Hong Kong.
Cathay International Holdings Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.